ESR1 and cancer: Some researchers also highlighted the impact of ER dysregulation on the efficacy of hormonal therapies in BRCA mutant cancers showing that alterations in ER expression or function could lead to resistance to agents like selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) [126, 127].